Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients’ lives.
Our Mission
To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek.
Our Vision
To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
Location: United States, Massachusetts, Boston
Employees: 51-200
Founded date: 1996
Investors 4
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Omega Fund... | omegafunds... |
| - | Hercules C... | htgc.com |
| - | Abingworth... | abingworth... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 05.03.2024 | Paratek Pharmaceuticals Announces Positive Efficacy Data for... | - | globenewsw... |
| 25.09.2023 | Gurnet Point Capital and Novo Holdings Acquires Paratek Phar... | Gurnet Point Capital and Novo Holdings A/S completed the acquisition of Paratek Pharmaceuticals (Nas... | finsmes.co... |
| 01.09.2022 | Paratek Pharmaceuticals to Present at the H.C. Wainwright 24... | BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercia... | globenewsw... |
| 14.03.2022 | Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of ... | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from... | globenewsw... |
| 01.06.2021 | PARATEK PHARMACEUTICALS, INC. Paratek Pharmaceuticals Annou... | - Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Pro... | marketscre... |
| 17.05.2021 | PARATEK PHARMACEUTICALS, INC. Paratek Pharmaceuticals Annou... | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% In... | marketscre... |